Senior Director

Model N expands into global market access through strategic partnership with CCX. Joint offering helps life sciences companies align launch strategy and commercial decisions across global markets REDWOOD CITY, Calif. - March 2, 2026 - Model N, the leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced a strategic partnership with CCX, a market leading technology company focused on accelerating global market access and pricing strategy. The partnership extends Model N's platform functionality into earlier phases of the drug lifecycle and expands the company's capabilities beyond pricing and market access operations into global launch pricing strategy. As a result, joint customers can more effectively coordinate pricing strategies and ensure timely launch execution in an increasingly complex regulatory and market access environment. The collaboration enables pharmaceutical manufacturers to quickly model, simulate, and coordinate launch strategies and commercial terms before products reach the market - a critical need as early access decisions can have downstream pricing and revenue implications across global markets. Model N's 2026 State of Revenue Report found that 99% of life sciences leaders say gross-to-net has become more complex. Yet many organizations still manage critical pricing and revenue processes through spreadsheets and manual workflows. This limits their ability to quickly evaluate trade-offs, anticipate cross-market impacts, and identify pricing risks from policies such as most-favored-nation (MFN) before decisions are made. "As gross-to-net complexity continues to rise, life sciences organizations need earlier alignment across market access, global pricing, and revenue planning," said Bret Connor, CEO of Model N. "Market access decisions shape the long-term revenue trajectory of a therapy, and by partnering with CCX, we're extending Model N's platform into global launch planning and strategy. This gives our customers greater visibility from initial market access discussions through execution and revenue management." By combining CCX's market access planning capabilities with Model N's pricing, tender, and revenue management solutions, manufacturers can align strategy across the product lifecycle and support end-to-end commercialization through launch, contracting, and loss of exclusivity. Under the partnership, CCX technology connects directly to Model N's global pricing and tender solutions. This allows manufacturers to model cross-market launch sequencing, evaluate MFN exposure, reference pricing impacts, and assess trade-offs before implementation using data-driven scenario modeling. The integration connects market access planning with contracting, tender management, and rebate processing within a coordinated framework. CCX's platform supports in the moment scenario modeling for launch and loss-of-exclusivity planning, collaboration between headquarters and affiliates, and structured payer negotiations. The company currently supports 76 pharmaceutical assets across 56 countries. "By working with Model N, we can connect market access planning directly to revenue execution," said Nathan Sigworth, CEO of CCX. "Together, we are helping manufacturers launch products more strategically, manage commercial decisions with greater confidence, and foster stronger collaboration with payers to ensure therapies reach the patients who need them." Editor details. * Company: * PharmiWeb * Name: * Editor Last Updated: 04-Mar-2026

Model N, a commercialisation and revenue optimisation platform for life sciences and high-tech companies, has appointed Dan Koellhofer as chief product officer and David Schur as chief technology officer. The move separates product and technology functions to accelerate innovation whilst maintaining platform reliability as the company scales. Koellhofer, formerly SVP of applications for sales and marketing at Anaplan, will lead product strategy and innovation. Schur, previously CTO at Blackstone portfolio company Sphera, will oversee engineering and platform strategy, including new agentic AI capabilities. The appointments follow recent additions to Model N's executive team, including a chief growth officer, chief financial officer and chief customer officer. The California-based company serves over 150 manufacturers across more than 120 countries.